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Redox balance(PXE) is an inherited disorder characterized by calciﬁcation of elastic ﬁbres leading
to dermatological and vascular alterations associated to premature aged features and to life threatening clinical
manifestations. The severity of the disease is independent from the type of mutation in the ABCC6 gene, and it
has been suggested that local and/or systemic factors may contribute to the occurrence of clinical phenotype.
The redox balance in the circulation of 27 PXE patients and of 50 healthy subjects of comparable age was
evaluated by measuring the advanced oxidation protein products (AOPP), the lipid peroxidation derivatives
(LOOH), the circulating total antioxidant status (TAS), the thiol content and the extracellular superoxide
dismutase activity (EC-SOD). Patients were diagnosed by clinical, ultrastructural and molecular ﬁndings.
Compared to control subjects, PXE patients exhibited signiﬁcantly lower antioxidant potential, namely
circulating TAS and free thiol groups, andhigher levels of parameters of oxidative damage, as LOOHandof AOPP,
and of circulating EC-SOD activity. Interestingly, the ratio between oxidant and antioxidant parameters was
signiﬁcantly altered in PXE patients and related to various score indices. This study demonstrates, for the ﬁrst
time, that several parameters of oxidative stress are modiﬁed in the blood of PXE patients and that the redox
balance is signiﬁcantly altered compared to control subjects of comparable age. Therefore, in PXE patients the
circulating impaired redox balance may contribute to the occurrence of several clinical manifestations in PXE
patients, and/or to the severity of disease, thus opening new perspectives for their management.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Pseudoxanthoma elasticum (PXE) is a genetic disorder character-
ized by calciﬁcation of elastic ﬁbres in all soft connective tissues [1],
withmain alterations in the dermis and in the vessel compartment [2].
The disease is due to mutations in the ABCC6 gene that codes for the
multidrug resistance protein-6 (MRP-6). The physiological role as well
as the pathogenesis of the disease are still unknown [3,4]. The high
heterogeneity of clinical manifestations, even in individuals of the
same family with identical mutations, suggests that local and/or
systemic factors might be involved.
Dermal ﬁbroblasts, although expressing little or no MRP-6 [5,6],
when isolated from PXE patients, exhibit a number of biochemical and
behavioural alterations compared to age matched controls indicating
that these cells bear permanentmetabolic alterations affecting synthesis39 059 2055426.
uali-Ronchetti).
ll rights reserved.and deposition of several matrix molecules, thus altering connective
tissue homeostasis and especially that of elastic ﬁbers[7–11].
Recently, it has been demonstrated that in vitro PXE ﬁbroblasts
suffer from a condition of mild chronic oxidative stress, as they pro-
duce more malondialdehyde, a byproduct of lipid peroxidation, and
have higher amounts of oxidised glutathione and of glutathione
peroxidase activity, as well as higher superoxide dismutase activity
[12] compared to controls.
In order to investigate whether the cellular impaired redox balance
could reﬂect a more generalized condition in patients, the redox equi-
librium in the blood of PXE patients was analyzed and compared with
controls of comparable age, by evaluating the amount of advanced
protein oxidation products (AOPP) and of lipid hydroperoxides (LOOH)
as indices of a general oxidative damage of plasma proteins, lipids and
lipoproteins; the total antioxidant status (TAS) and the total thiol
content representing the capacity of plasma factors to counteract
oxidative stress; the activity of extracellular superoxide dismutase (EC-
SOD), due to its important role in controlling damages induced by
superoxide anion radicals [13,14].
Table 1
Clinical data of patients
Patients' gender/age Clinical scores Mutations
Allele 1 Allele 2
M/10 S2E2 c.3413GNA (p.R1138Q) c.3413GNA (p.R1138Q)
F/16 S1 c.1171ANG (p.R391G) c.1552CNT (p.R518X)
F/18 S3E2V2 c.1484TNA (p.L495H) c.1484TNA (p.L495H)
F/21 S2E2 c.2420GNA (p.R807Q) ND
F/21 S2E2 c.184TNC (p.Y62H) c.2996_4208del
(p.A999_S1403del)
F/24 S2E2 c.1799GNA (p.R600H) c.2420GNA (p.R807Q)
F/27 S3E2 c.184TNC (p.Y62H) c.2996_4208del
(p.A999_S1403del)
F/30 S2E2G1 c.2996_4208del
(p.A999_S1403del)
c.4198GNA (p.E1400K)
F/30 S2E3 c.2996_4208del
(p.A999_S1403del)
c.4198GNA (p.E1400K)
M/30 S2E1 c.3421CNT (p.R1141X) c.3735GNA
F/32 S2 c.3421CNT (p.R1141X) c.3735GNA
F/33 S3E2 c.1987GNA (p.G663S) ND
F/33 S3E3 c.1609_1609delG
(p.V537fsX26)
c.1763_1769del ins56
F/36 S3E2V3 c.3421CNT (p.R1141X) ND
F/36 S3E3V2G1 c.3421CNT (p.R1141X) c.3421CNT (p.R1141X)
M/39 S1E2V2 c.1552CNT (p.R518X) c.2996_4208del
(p.A999_S1403del)
M/42 S1E3V2G1 c.1552CNT (p.R518X) c.2996_4208del
(p.A999_S1403del)
F/43 S3E3 c.1552CNT (p.R518X) c.1552CNT (p.R518X)
F/44 S3E2 c.3341GNA (p.R1114H) c.3542GNA (p.G1181D)
F/45 S3E3V2C1G1 c.3421CNT (p.R1141X) c.3421CNT (p.R1141X)
F/48 S2E2V2 c.1553GNA (p.R518Q) ND
M/51 S1E3 c.3662GNA (p.R1221H) ND
F/52 S3E3V2 c.3088CNT (p.R1030X) c.3088CNT (p.R1030X)
M/54 S1E2G1 c.1799GNA (p.R600H) c.3941GNA (p.R1314Q)
F/56 S3E3V2 c.3662GNA (p.R1221H) ND
F/60 S2E3V2C1G1 c.951CNA (p.S317R) c.3421CNT (p.R1141X)
F/62 S2E3 c.1552CNT (p.R518X) c.3421CNT (p.R1141X)
Scores describe the severity of clinical manifestations.
In particular, for the skin, S1 denoted the presence of papules on the neck and/or other
ﬂexural sites, S2 the presence of coalescent papules (or plaques) and S3 lax, redundant
skin.
For the eyes, E1 denoted peau d'orange, E2 angioid streaks and E3 retinal haemorrhages
and disciform scarring.
For the vascular system, V1 was given to weak or absent pulses, V2 to intermittent
claudication and V3 to vascular occlusion or other symptoms requiring surgery.
For cardiac symptoms, C1 denoted electrocardiographic changes of ischemia and/or
angina, and C2 myocardial infarction.
For the gastrointestinal system, G1 was given to any gastrointestinal bleeding for which
no cause other than PXE could be found.
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2.1. Chemicals
All reagents were purchased, unless otherwise speciﬁed, from Sigma (St. Louis, MO)
and were of analytical grade.
2.2. Plasma and dermal samples
Blood samples from 27 patients with pseudoxanthoma elasticum (21 women and 6
men; 37±12 yr) and from 50 healthy volunteers (40 women and 10 men; 41±10 yr)
were analysed. All subjects gave written informed consent and the investigation was
approved by the Local Ethical Committee.
Venous blood samples were drawn after 8 h fasting and collected into tubes
containing EDTA or Gel-Clot Activator. Tubes were centrifuged at 3500 ×g for 10 min at
4 °C. Appropriate aliquots of plasma-EDTA and of serumwere stored at −70 °C and used,
according to the method applied for each marker.
2.3. Diagnosis and clinical evaluations
PXE patients have been ﬁrstly clinically diagnosed on the basis of skin and eye
alterations. Other clinical signs, such as intermittent claudication, cardiovascular
complications and gastrointestinal bleeding were carefully evaluated when present.
In order to uniformly describe these parameters, physicians employed an inter-
nationally standardized scoring system (Phenodex™) developed by the PXE In-
ternational Consortium [4]. The “total score” used in the present study was the sum
of all scores that, in each patient, characterised the alterations of the different
organs/systems, and therefore a global index of the severity of clinical manifestation
in each individual. Diagnosis was further conﬁrmed by light and electron mi-
croscopy on skin samples and by the identiﬁcation of mutations in the ABCC6 gene
according to the procedures already described [3]. Disease onset in all patients
occurred around puberty. Clinical data and genotypes for each patient are reported
in Table 1.
2.4. Analytical methods
2.4.1. Evaluation of plasma advanced oxidation protein products (AOPP)
Plasma AOPPs were evaluated using a microassay adapted to Cobas Mira ac-
cording to Matteucci et al. [15] and based on the original method ofWitko-Sarsat et al.
[16]. Brieﬂy, 18 µL of plasma or chloramine-T (ch-T) standard solutions (400–
6.25 µmol/L) were placed in each well of the Cobas Mira autoanalyser followed by
addition of 200 µL of reaction mixture, consisting of 81% phosphate buffer solution
(PBS), 15% acetic acid, and 4% 1.16 mM potassium iodide. Absorbance was read at
340 nm (the blank contained PBS instead of plasma). AOPP concentration was
obtained on the basis of measured ch-T equivalents. Intra- and inter-assay variation
coefﬁcients were 1% and 5%, respectively.
2.4.2. Evaluation of serum lipid hydroperoxides (LOOH)
Lipid hydroperoxides were evaluated by the FOX2 method (Ferrous Oxidation)
automated by Arab and Steghens [17] adapted to Cobas Mira (wavelength 600 nm) for
studying lipid peroxidation in serum samples. Xylenol orange (180 μL of a 167 μM
solution) was added to 25 μL of sample. The ﬁrst optical readingwas recorded before the
addition of 45 μL of 833 μM iron II D-gluconate. LOOH was calculated using a standard
curve of tert-butylhydroperoxide. Intra- and inter-assay variation coefﬁcients were 3%
and 8%, respectively.
2.4.3. Total antioxidant status (TAS)
The total antioxidant capacity of serum was estimated using the commercial kit
‘total antioxidant status’ (Randox, UK), adapted to the autoanalyser Cobas Mira (ABX,
France), which measures at 600 nm the formation of the radical cation ABTS+ using the
Reagent ABTS® in the presence of H2O2 and peroxidase [18]. The methodwas calibrated
using the TROLOX standard included with the kit.
2.4.4. Determination of plasma sulfhydryl groups (total thiol)
Plasma sulfhydryl (-SH) groups were determined by using Ellman's reagent 5,5′-
dithiobis(2-nitrobenzoate)-DTNB adapted to Cobas Mira [19]. Plasma (10 µL) was mixed
with 200 µL of 0.1 M Tris buffer, containing 10 mM EDTA, pH 8.2. The absorbance at
405 nm, given by the plasma alone, was subtracted from that obtained from the same
sample 10min after addition of 8 µL of 10 mMDTNB. A blank containing only DTNB was
also included, and -SH concentration was calculated by using a standard curve of
glutathione. Intra- and inter-assay variation coefﬁcients were 1.2% and 6%, respectively.
2.4.5. Separation of extracellular superoxide dismutase (EC-SOD)
EC-SOD (EC 1.15.1.1) can be separated from SOD isoenzymes and other compounds
having SOD-like activity applying the chromatography of samples on concanavalin A-
substituted Sepharose (ConA-Sepharose; Amersham, NL). EDTA-plasma (200 µL) [14]
was applied to a 1 mL ConA-Sepharose column equilibrated with 50 mM Na-HEPES
(pH 7.0)–0.25 M NaCl. After 5 min, 3 mL of equilibration buffer were added, the eluted
ﬂuidwas discarded and the columnwaswashedwith 10mL of equilibration buffer. EC-
SODwas ﬁnally eluted with 5 mL of 0.5 Mα-methylmannoside added to 1mL aliquots
at 5 min intervals.2.4.6. EC-SOD activity determination
Brieﬂy, 160 µL of eluted plasma were processed using a system based on the
oxidation of NAD(P)H [20], adapted to Cobas Mira. Brieﬂy, plasma was combined with
160 µL of 100mM triethanolamine/diethanolamine–HCl buffer, pH 7.4, 5 µL of a solution
containing 100 mM EDTA and 50 mMMnCl2, and 8 µL of 7.5 mM NAD(P)H. The reaction
was started by addition of 20 μL of 10 mMmercaptoethanol. Superoxide was generated
by molecular oxygen in the presence of EDTA, MnCl2, and mercaptoethanol. NAD(P)H
was oxidised by superoxide at a predictable rate and the absorbance at 340 nm
decreased accordingly. The decrease in absorbance was inhibited by the presence of
endogenous EC-SOD. Samples were tested for NAD(P)H oxidase activity before addition
of mercaptoethanol. EC-SOD activity was estimated from a standard curve constructed
bymeasuring the activity of increasing known amounts of Cu/Zn-SOD (Sigma). One unit
was equivalent to 21.5 ng Cu/Zn-SOD and resulted in a 50% inhibition of the rate of NAD
(P)H oxidation compared with triethanolamine/diethanolamine buffer as a negative
control. Intra- and inter-assay variation coefﬁcients were 2.5% and 8%, respectively.
2.5. Statistical analysis
All determinations were performed in duplicate and data were expressed as
mean±SEM.
The Pearson's test was used to assess the signiﬁcance of correlations between ana-
lytical values, age and clinical scores. Correlations were also evaluated by the Fisher test.
In order to verify if mean values of oxidative stress markers belonged to different
populations, differences in the distribution of data were compared with the Student t
test (critical value of t=1.66 with 75 d.f. and probability 0.95).
Fig. 1. Power regression lines shows the distribution of different markers of oxidative stress. AOPP (advanced oxidation protein products, A, a), LOOH (lipid peroxidation derivatives, B, b),
TAS (total antioxidant status, C, c), thiol content (D, d) and EC-SOD (extracellular superoxide dismutase activity, E, e) weremeasured in the blood of controls (A, B, C, D, E, F) and PXE
patients (a, b, c, d, e, f) in relation to the age of subjects. There was no signiﬁcant correlation betweenmeasured values and age of individuals, except for the total thiol content that
signiﬁcantly (pb0.001) decreased with age in controls (D) and the advanced oxidation protein products (AOPP) that were signiﬁcantly (pb0.05) increasedwith age in patients (a).
Values expressed as mean values±SE are reported in the upper part of the ﬁgure for control subjects and for PXE patients. ⁎pb0.05, ⁎⁎pb0.01, ⁎⁎⁎pb0.001.
Fig. 2. The total thiol content (a) and the AOPP level (b) were compared in control and
PXE patients according to the decade of life of individuals. The thiol content was always
lower in patients up to the ﬁfth decade of life, whereas AOPP levels were always higher
in patients after the third decade of life. ⁎pb0.05.
476 M.I. Garcia-Fernandez et al. / Biochimica et Biophysica Acta 1782 (2008) 474–481Finally, the inﬂuence of gender, age and clinical scores on analytical values was
evaluated with the two and three way analysis of variance. Statistical signiﬁcance was
conﬁrmed for pb0.05.
3. Results
3.1. Measurement of parameters of oxidative stress
Several parameters of oxidative stress, i.e. advanced oxidation
protein products (AOPP), lipid peroxidation products (LOOH), total
antioxidant status (TAS), total thiol content and the EC-SOD activity,
were measured in the blood of PXE patients and of healthy subjects of
comparable age.
Mean values indicate that all parameters were signiﬁcantly mod-
iﬁed in patients (Fig. 1). In particular, AOPP and LOOH, as indices of
oxidative damage of proteins and lipids, were signiﬁcantly higher in
PXE patients, whereas the antioxidant capacity of plasma, namely TAS
and total thiol content, were signiﬁcantly lower in patients, compared
to controls (Fig. 1). Moreover, the EC-SOD activity was signiﬁcantly
higher in the plasmaof PXEpatients than in healthy individuals (Fig.1).
Although the great majority of patients were women, the analysis
of variance allowed to exclude the inﬂuence of gender in the eval-
uation of oxidative stress parameters between control and PXE
patients (data not shown).
In order to assess if these parameters were differently distributed
according to the age of subjects, values from each individual (controls
and patients) were evaluated by linear regression analysis (Fig.1). Data
indicate that age seems to inﬂuence total thiol content in control
subjects (pb0.001) (Fig. 1D) and AOPP values in patients (pb0.05)(Fig. 1a), whereas all other parameters did not appear to change with
age in healthy individuals nor in PXE patients (Fig. 1).
Looking atmean values of thiols and AOPP in each decade of life, we
have observed that the total thiol content was signiﬁcantly different in
the third and fourth decades of life and became similar in healthy and
diseased subjects after the ﬁfth decade of life (Fig. 2a). The opposite
behaviour was noted for AOPP values that were similar in controls and
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dissimilar after the third decade, being signiﬁcantly different only in
the sixth decade of life (Fig. 2b).
The analysis of variance conﬁrmed that the different thiol content
in control and PXE patients is partly related to the occurrence of the
disease and partly to aging itself.
3.2. Parameters of oxidative stress and severity of disease
Although all patients included in the present study exhibited the
ﬁrst sign of the disease around puberty, the severity of the disease as
well as the number of organs involved appeared to progress with
time in patients at different degree, independently from the type of
mutation.
Fig. 3 describes the relationships between patients' age and the
disease score measured in the different affected organs/system (i.e,
skin, eyes, peripheral vessels, heart and gastrointestinal tract) as well
as the total disease score (i.e. the sum of all scores that, in each patient,
characterized the alterations of the different organs/systems).
It appears that some organs showan age-dependent progression of
clinical manifestations. In particular, the eye score (pb0.004), the
peripheral vessel score (pb0.05) and the total disease score (pb0.01)
signiﬁcantly correlate with age. By contrast, the skin score did not
change with age as well as the cardiac and the gastrointestinal score,
even though the number of patients with cardiac and gastric com-
plications was probably too low for a signiﬁcant correlation.
Furthermore, in order to assess if oxidative stressmarkers were not
only associated to the occurrence of PXE, but if they were also related
to the severity of disease, all investigated parameters were correlated
with the patient's total disease scores (Fig. 4). Data indicate that there
was a statistically inverse correlation between the total disease score
and the thiol content (Fig. 4d) (pb0.02). The thiol levels were inversely
related also to the skin score (pb0.01) (not shown). By contrast, all
other values did not signiﬁcantly correlate with the overall severity ofFig. 3. Power regression lines showing the distribution of disease scores according to the age
in peripheral vessels, in the heart and in the gastrointestinal tract were evaluated for each p
characterized the alterations of the different organs/systems (see also Methods). The eye (p
progress with the age of patients.the disease, nor with the severity of clinical manifestations of each
organ, at least in the cohort of patients we have examined (data not
shown).
Analysis of variance indicated that changes in thiol levels were
partly related to the age of patients and partly to the disease score,
with the exception of the skin score that appeared to be independent
from age (data not shown).
3.3. Oxidant/antioxidant ratio in PXE patients
The ability of organisms to cope with oxidative damage depends
on the efﬁciency of the antioxidant capabilities within tissues and/or
blood to counteract oxidative damages. We have therefore evaluated
the redox balance by correlating the oxidant/antioxidant ratio (OX/
AntiOX ratio) by comparing parameters of oxidative damage (AOPP
and LOOH) with those of antioxidant properties (TAS and total
thiols). Data indicate that the mean OX/AntiOX ratio is 0.99±0.04 in
control subjects, whereas it is 1.32±0.08 (pb0.004) in PXE patients
(Fig. 5).
Even though there is an age-dependent increase of the OX/AntiOX
ratio in controls (pb0.02) as well as in patients (pb0.03), values are
always higher in PXE, at all ages considered (Fig. 5).
Difference between control and PXE patients can be even more
pronounced if we consider the circulating EC-SOD as a parameter
favouring oxidative damage in tissues. In these conditions, the ratio
betweenparameters of oxidative damage (AOPP, LOOHandEC-SOD) and
antioxidant parameters (TAS and total thiols) is 1.09±0.04 vs 1.48±0.08
(pb0.001).
Interestingly, in PXE patients the OX/AntiOX ratio appears to
be signiﬁcantly related not only to the total disease score (pb0.02) but
also to the skin (pb0.05), the heart (pb0.01) (Fig. 6). and the car-
diovascular score (pb0.05, data not shown), being this last score
calculated from all vascular complications, such as vessel occlusions,
claudicatio, cardiac complications, gastrointestinal bleeding.of patients. The score indices of clinical manifestations occurring in the skin, in the eyes,
atient. Moreover, the total score was taken as the sum of all scores that, in each patient,
b0.004), the vascular (pb0.05) and the total scores (pb0.01) appeared to signiﬁcantly
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but with different disease score and/or number of organs involved,
there was a general correlation between the severity of the disease
and the OX/AntiOX ratio (Table 2).
4. Discussion
Data from the present study demonstrate for the ﬁrst time that
different parameters of the redox status are signiﬁcantly modiﬁed in
the circulation of PXE patients compared to control subjects of
comparable age and that the oxidant/antioxidant ratio (OX/AntiOX
ratio) signiﬁcantly increased in patients. These ﬁndings are consistent
with recent evidence from our laboratory showing that PXE dermal
ﬁbroblasts in vitro are in a condition of mild chronic oxidative stress
[12]. Therefore, a condition of permanent oxidative stress is actually
present and not efﬁciently balanced in PXE patients at local and at
general levels.
It is well known that oxidative stress is associated to age-related
degenerative features in several tissues and organs [21]. All patients
included in the present study showed ﬁrst sign of clinical manifesta-
tions at puberty and, for most of them, there was a progression of
disease's severity with time, as clearly shown by the positive cor-
relation between patient's age and total disease score.
Interestingly, as in the case of skin, it appeared that some organs
did not show a signiﬁcant correlation between age and progression of
clinical manifestations.
In the normal population, vessel alterations are not clinically
relevant until the ﬁfth or the sixth decades of life [22]. By contrast,
from the analysis of patients' clinical data it appears that 25% of
patients (7/27) had vascular alterations before the ﬁfth decade of life,
and 13% (4/27) before the fourth decade of life. Moreover, claudication
due to femoral artery damages is often present in PXE patients in the
second–third and, occasionally, also in the ﬁrst decade of life [2,3].
The majority of investigated parameters of the oxidative state did
not change with age in the group of subjects we analyzed. This could
be due to the relatively low number of old individuals since no one
was over the age of 67 yr. Moreover, the heterogeneity among subjects
may hide differences related to aging. Never the less, patients were
always compared with controls of similar age and in some cases data
were analyzed also within each decade of life.
Even though ROS are physiologically important mediators in bio-
logical signaling processes [23], they may also represent an important
cause of structural damage. Harman has been the ﬁrst to propose that
the damaging effects of ROS may play a key role in the mechanism of
aging [24], since ROS are continuously generated in living tissue and
can potentially damage DNA, proteins and lipids, thus possibly
inﬂuencing life span [25,26]. Even though PXE patients are character-
ized by several features resembling premature aging syndromes (i.e.
skin wrinkles and laxity, cardiovascular complications, visual impair-
ment similar to macular degeneration), at present, we do not have any
signiﬁcant data on premature death in clinically and/or genetically
diagnosed PXE patients. Therefore, the altered oxidant/antioxidant
balance in these patients could be eventually related only to the pre-
mature occurrence of clinicalmanifestations that can inﬂuence at least
life's quality, if not life span expectancy.
The antioxidant imbalance in PXE plasma is shown by the sig-
niﬁcantly lower level of thiols (namely glutathione, cysteine and
protein-bound sulphydryl groups, albumin) detected in patients com-
pared to controls. Thiols are recognized to play a fundamentalFig. 4. Correlation between the total score, representing the severity of clinical
complications as well as the number of organs involved, and AOPP (advanced oxidation
protein products, a), LOOH (lipid hydroperoxides, b), TAS (total antioxidant status, c),
total thiol content (d) and EC-SOD (extracellular superoxide dismutase, e). A power
regression line is shown in each panel and parameters appeared to be signiﬁcantly
(pb0.02) related to the total disease score only in the case of total thiol content (d).
Fig. 5. Correlation between the oxidant/antioxidant ratio (OX/AntiOX ratio) and the age of control subjects (a, pb0.02) and of PXE patients (b, pb0.03). The increase of the OX/AntiOX
ratio is more evident in patients at all ages examined (C). Mean values±SE are reported in panels a and b (pb0.004). ⁎pb0.05.
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against oxidative stress [27]. Their level normally decreaseswith age in
humans as well as in mice [28] and this may contribute to the reduced
capacity of plasma factors to counterbalance oxidative stress during
senescence. Interestingly, thiol levels in young patients were generally
as low as in normal old individuals. This ﬁnding and the inverse cor-
relation between plasma thiol content and severity of clinical
manifestations may highlight the importance of this parameter in
the premature occurrence of clinical manifestations in PXE patients.
Since the great majority of thiol groups are furnished by plasma
proteins, the net decrease of the thiol content in PXE plasma is
probably the result of abnormal oxidation of SH-containing proteins
[29]. This ﬁnding is consistent with the high amount of AOPP inFig. 6. Power regression lines showing the distribution of disease scores according to the OX/A
in peripheral vessels, in the heart and in the gastrointestinal tract were evaluated. Moreover,
alterations of the different organs/systems (see also Methods). The skin (pb0.05), the heart
AntiOX ratio.patients, similarly to what observed in the plasma of uremic patients
[16] and in those with coronary artery disease [30], where the AOPP
parameter has been used as indicator of oxidant-mediated protein
damage. The present study shows that, in PXE, the permanent
condition of oxidative stress affects also plasma lipids, as documented
by the higher level of LOOH. Since lipoproteins account for themajority
of plasma lipids, data suggest that oxidised lipoproteins could con-
tribute to the precocity and severity of vessel alterations that are
frequently and prematurely observed in PXE patients [2,3].
To further investigate the reduced capacity of PXE patients to cope
with a generalized condition of oxidative stress, we have evaluated the
activity of EC-SOD. Superoxide dismutases are enzymes that catalyse
the rapid dismutation of superoxide radical to hydrogen peroxide andntiOX ratio. The score indices of clinical manifestations occurring in the skin, in the eyes,
the total score was taken as the sum of all scores that, in each patient, characterized the
(pb0.01) and the total scores (pb0.01) appeared to be signiﬁcantly related to the OX/
Table 2
Oxidant/antioxidant ratio in PXE patients with identical mutations and different severity of disease
ABCC6 mutations ABCC6 mutations Age Gender Total disease score No. affected organs OX/AntiOX Ratio
Allele 1 Allele 2
c.184TNC (p.Y62H) c.2996_4208del (p.A999_S1403del) 21 F 4 2 0.80
c.184TNC (p.Y62H) c.2996_4208del (p.A999_S1403del) 27 F 5 2 1.19
c.2996_4208del
(p.A999_S1403del)
c.4198GNA (p.E1400K) 30 F 5 2 1.10
c.2996_4208del
(p.A999_S1403del)
c.4198GNA (p.E1400K) 30 F 5 3 1.09
c.3421CNT (p.R1141X) c.3735GNA 32 F 2 1 0.91
c.3421CNT (p.R1141X) c.3735GNA 30 M 3 2 1.42
c.1552CNT (p.R518X) c.2996_4208del (p.A999_S1403del) 39 M 5 3 1.29
c.1552CNT (p.R518X) c.2996_4208del (p.A999_S1403del) 42 M 7 4 1.42
c.3421CNT (p.R1141X) c.3421CNT (p.R1141X) 36 F 9 4 1.62
c.3421CNT (p.R1141X) c.3421CNT (p.R1141X) 45 F 10 5 1.90
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cell types [31] and is the only antioxidant enzyme that removes
superoxide radicals from the extracellular space of tissues [31]. Several
reports have shown that high levels of circulating EC-SOD are asso-
ciatedwith decreased tissue antioxidant levels andwith increased risk
of ischemic diseases indicating that the circulating form of EC-SOD is
not efﬁcient in protecting tissues [32]. PXE patients had always high
levels of circulating EC-SOD compared to controls. The high level of EC-
SOD in PXE plasma could derive either from its release from tissues by
proteolytic removal of its heparin-binding site [33] or by mechanisms
involving binding of EC-SOD to sulphated glycosaminoglycans that are
abundantly present in plasma and urine of PXE patients [11].
Even though vascular alterations are frequently observed in PXE
patients, circulating EC-SOD did not appear to be signiﬁcantly related
to vascular nor to other clinical manifestations. Nevertheless the high
level of circulating EC-SODmay be regarded as a factor contributing to
oxidative damage, further worsening the altered redox balance in PXE
patients, as suggested by the striking divergence in the ratio between
oxidant and antioxidant parameters measured in controls and in PXE
patients.
The redox balance within tissues or in the circulation is due to a
tightly regulated homeostasis between oxidant and antioxidant
capabilities. By evaluating the OX/AntiOX ratio, i.e. ratio between
measured values of oxidative damage (AOPP and LOOH) and of anti-
oxidant properties (TAS and total thiols), it emerges that the OX/
AntiOX ratio is related to the total disease score and to skin and cardiac
complications. Moreover, in PXE patients with identical ABCC6 muta-
tions, the total severity of clinical manifestations generally showed a
positive correlation with levels of the OX/AntiOX ratio. This sustains
the hypothesis that factors other than ABCC6 mutations may con-
tribute to the heterogeneity of clinical manifestations and that OX/
AntiOX ratio may play a relevant role.
In conclusion, present data demonstrate that abnormalities in the
redox equilibrium are present in the circulation of PXE patients,
affecting both plasma proteins and lipids, consistently with previous
observations on in vitro cultured ﬁbroblasts [12] and with very recent
data from Zarbock et al. showing that the disease onset in PXE patients
could be related to polymorphisms in genes encoding for catalase,
superoxide dismutase 2 and glutathione peroxidase 1 [34]. Alterations
in the plasma redox balance have been repeatedly associated to age-
related complications [35] and in particular to vascular damages [36].
Vascular complications are present and have been repeatedly ob-
served in PXE [2,3], and the plasma redox imbalance could contribute
to these vascular alterations; actually, claudication and femoral cal-
ciﬁcations are often present in PXE patients already in the second and
the third decades of life.
In the light of these results, it is conceivable to suggest that PXE
manifestations are not the direct effect of the reduced/absent ex-
pression and function of MRP6, since connective tissue alterations,and in particular elastic ﬁber calciﬁcations, are the consequence of
an alteredmetabolism of mesenchymal cells, where MRP6 is actually
poorly expressed, even in normal conditions [37]. Therefore, the
pathologic behaviour of ﬁbroblasts could be the consequence of a
modiﬁed “environment”, i.e. of an increased redox imbalance either
general and/or local. The response of cells to oxidative stress might
have epigenetic consequence on cell behaviour through altered DNA
methylation, abnormal regulatory mechanisms possibly by miRNA,
accumulation of oxidised proteins and activation of an ER stress
response.
However, it has to be mentioned that increased ROS production is
present in several disorders where no calciﬁcation occurs, or where
mineralization is only limited to the cardiovascular system [21,38].
Therefore, oxidative stress per se, could not be the only responsible for
calciﬁcation of elastic ﬁbers.
In PXE, it has been recently observed that, as a consequence and/or
in association with oxidative stress, are changes in the pathways
regulating the carboxylation of Matrix Gla Protein (MGP) that, when
efﬁciently carboxylated, acts as a potent inhibitor of ectopic calciﬁca-
tion in soft connective tissues [39].
At present, studies are in progress in order to verify if the same
molecular pathways are altered also in patients with PXE-like alter-
ations, such as in haemolytic disorders and especially in beta-
thalassemia where PXE-like structural and clinical manifestations
have been described in several organs[40–42] and where increased
markers of oxidative stress have been already demonstrated [43].
Since a globally preserved antioxidant ability is a fundamental
prerequisite for a successful ageing, it could be suggested that, as
already done in similar conditions of oxidative stress [44], antioxidant
treatments could ameliorate the redox balance in PXE, thus opening
new perspectives for the management of clinical complications.
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